Situation: CMS is pushing ACCESS from a narrow tech-enabled payment experiment toward a broader chronic-condition platform. The agency will add COPD, substance use disorder, and tobacco cessation to the model in 2027, according to Healthcare Dive and the AHA. That makes ACCESS the day’s most consequential development for Value-Based Contracting, Care Coordination, and Medicare Payment Policy. The Trump administration’s CMS—under Administrator Dr. Mehmet Oz, with Abe Sutton leading CMMI—is signaling that digitally enabled chronic care models will not stay condition-by-condition pilots if they can support broader alignment across Medicare and potentially Medicaid. In parallel, the Peterson Health Technology Institute questioned whether virtual kidney-care vendors meaningfully slow disease progression or reduce costs, prompting industry pushback reported by Fierce. The combined message: CMS is expanding tech-enabled payment models, while independent evaluators are raising the evidence bar for digital care vendors.

Background: ACCESS matters because it sits at the intersection of chronic disease management, technology-enabled care, and federal payment experimentation. CMS’s move to add behavioral and pulmonary conditions expands the model beyond traditional medical management into areas where utilization, adherence, social risk, and engagement drive total cost of care. That is strategically important for organizations building Population Health Management capabilities, because success will depend less on app deployment and more on closed-loop workflows, medication management, behavioral health integration, and longitudinal attribution. The PHTI kidney-care report reinforces the same point: digital enablement is not synonymous with value creation. Vendors and risk-bearing providers will increasingly need condition-specific proof of lower avoidable utilization, improved progression metrics, and credible savings—not just engagement statistics. Meanwhile, the NAACOS ACCESS Coalition underscores that ACO stakeholders see ACCESS as more than a technology model; they view it as a potential bridge between specialty care, primary care, and accountable payment design.

Assessment: The important pattern is not “more innovation models.” It is CMS tightening the link between technology, chronic disease, and accountable payment while the market becomes less tolerant of weak ROI claims. ACCESS’s expansion suggests CMMI is looking for scalable model architecture: modular conditions, standardized incentives, and eventual cross-payer applicability. That fits the current Trump administration’s stated posture around efficiency and technology, including CMS interest in AI and operational modernization under leaders such as Jacob Schiff, CMMI Chief AI & Technology Officer. But the PHTI findings are a warning shot for vendors selling into ACOs, MA plans, and health systems: if virtual care cannot demonstrate impact on cost, progression, or quality, it will be treated as administrative spend—not VBC infrastructure. This also raises the stakes for Quality Metrics. COPD, substance use disorder, and tobacco cessation require outcome measures that are harder to capture than claims-based utilization but more meaningful than process compliance. The winners will be organizations that can pair digital interventions with real care teams, claims/clinical data integration, and contract terms tied to measurable impact. The losers will be point solutions unable to survive procurement scrutiny from CFOs and payer actuaries.